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ABSTRACT
The follow up of patients on active surveillance requires to repeat prostate 
biopsies. Predictive models that identify patients at low risk of progression or 
reclassification are essential to reduce the number of unnecessary biopsies. The aim 
of this study is to validate the Prostate Active Surveillance Study risk calculator 
(PASS-RC) in the multicentric Spanish Urological Association Registry of patients on 
active surveillance (AS), from common clinical practice.
Results: We find significant differences in age, PSA and clinical stage between 
our validation cohort and the PASS-RC generation cohort (p < .0001), with a 
reclassification rate of 10–22% on the follow-up Bx, no cancer was found in 43% of 
the first follow-up Bx. The calibration curve shows underestimation of real appearance 
of reclassification. The AUC is 0.65 (C.I.95%: 0.60–0.71). PDF and CUC do not suggest 
a specific cut-off point of clinical use.
Methods: We select 498 patients on AS with a minimum of one follow-up biopsy 
(Bx) from the 1,024 males registered by 36 Spanish centers recruiting patients on 
the Spanish Urological Association Registry on AS. PASS-RC external validation is 
carried by means of calibration curve and area under de ROC-curve (AUC), identifying 
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cut-offs of clinical utility by probability density functions (PDF) and clinical utility 
curves (CUC).
Conclusions: In our first external validation of the PASS-RC we have obtained 
a moderate discrimination ability, although we cannot recommend cut-off points of 
clinical use. We suggest the exploration of new biomarkers and/or morpho-functional 
parameters from multiparametric magnetic resonance image, to improve those 
necessary tools on AS.
INTRODUCTION
Active surveillance (AS) is increasingly being 
implemented by urologists as a strategy that provides 
the benefits from prostate cancer (PCa) opportunistic 
screening observed in western countries [1], but avoids 
overtreatment. We have presented our National Registry 
(AEU/PIEM/2014/0001, www.piem.aeu.es) supported by 
the Spanish Urological Association (Asociación Española 
de Urología, AEU) [2]. This initiative was created with the 
aim of facilitating the implementation of AS in all types of 
Hospitals, and of providing an opportunity for multicentric 
clinical research, as different inclusion criteria and follow-
up strategies are allowed. These wider inclusion criteria 
are contemplated in other AS registers such as the Canary 
Prostate Active Surveillance Study (PASS) [3], in contrast 
with the more strict inclusion criteria used by previous 
series [4–10].
All the different AS protocols coincide on the 
necessity to perform repeated prostatic biopsies (Bx) 
which are not free of complications [11], with increasing 
antibiotic resistance as a major problem. Recently, 
the initial results of the PASS study (clinicaltrials.gov 
NCT00756665) have been published, with a median 
follow-up of 28 months: 24% of their patients faced 
adverse reclassification [3]. These data are frequently 
found in a current database like ours [2] among others 
[12, 13], all of which have been previously driven by 
the uncertainty of the common selection criteria used. 
Using a cohort of 859 Gleason 6 PCa patients, in their late 
study the same group has proposed an easy to use online 
prediction tool [14] of progression in AS, with widely 
used and reproducible covariates. This tool showed an 
area under the curve (AUC) of 72.4% for reclassification 
in the follow-up Bx, providing an on-line tool to facilitate 
counselling for the patients on AS [15].
Although new biomarkers and data from 
multiparametric Magnetic Resonance Imaging (mpMRI) 
could improve its predictive accuracy [16–19], the real 
strength of this new tool relies on its variables: age, PSA, 
months from last biopsy, percentage of positive cores 
for PCa on the last Bx and number of prior negative Bx; 
all of them available and reproducible elsewhere. Both 
criteria, new biomarkers such as PCA3 and PHI [20] 
and mpMRI [21], have shown their ability for a better 
selection of patients for AS when referred to pathological 
results of radical prostatectomy specimens, but they 
will need to demonstrate clear advantages in gaining 
accuracy, but also their cost-effectiveness, if they are to 
be regularly introduced in AS protocols. Without mpMRI 
and new biomarkers and using just the criteria utilized in 
this model, the long term results of the AS series show 
excellent disease-free survival results [19].
As the PASS and AEU protocols are comparable 
in their design [2, 3], we aim to perform an external 
validation of this PASS-RC with a different population. 
We understand that our external validation study specially 
focused on defining clinical utility of PASS-RC could 
make this tool a useful help for decision making in men 
on AS.
RESULTS
From the 1,024 Prostate cancer patients recruited 
in the PIEM cohort until December 31st 2015, only 
498 of them had at least one follow-up Bx to evaluate 
the possibility of Bx reclassification by the PASS-RC. 
These 498 patients form the validation set and come 
from 24 Spanish hospitals, the median follow-up was 
19.7 months with 25%–75% percentiles of 11.4 and 33.7 
months, respectively. Among them, the patients without 
reclassification had a median follow-up until last biopsy of 
11.7 months, with P25–75 of 7.2–18.3. The median time 
between reclassification and first biopsy was 9.5 months 
with P25–75 of 7–16.7 months. We observed statistically 
significant differences for the distribution of variables age, 
race, PSA and T stage at diagnosis between both cohorts 
(Table 1).
Our cohort had a maximum of four follow-up Bx 
(Table 2), with slightly superior patient mean age at the 
different biopsies. The follow-up Bx had been performed 
at a mean of 2 months before in the AEU cohort. The 
mean PSA value was approximately 1 ng/ml greater in our 
series. The number of biopsy cores had the same mean 
12 cores for the diagnostic biopsy at both series, but our 
validation cohort practiced significantly more cores at the 
follow-up-Bx.
The analysis of the variables that define 
reclassification shown in Figure 1 illustrates the 
percentages of reclassification for the PIEM and PASS 
database at the four follow-up biopsies. The calculated 
p-values of 0.92, 0.23, 0.12 and 0.99 respectively 
also reflect the equivalence between percentages of 
reclassification in all follow-up biopsies.
As regards the validation of the PASS-RC, 
we obtained the calibration curve that shows an 
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underestimation of reclassification probabilities 
(Figure 2). The ROC curve resulted in an area under the 
ROC curve (AUC) of 0.65, lower than the 0.72 obtained 
in the generation cohort [15] (Figure 3). No statistically 
significant differences appear in a comparison between 
Gleason 3+4 (AUC = 0.66) and Gleason 4+3 (AUC = 
0.63) reclassifications, p-value = 0.55.
Figure 4 shows the probability density function 
(PDFs) analysis performed. We can see the probabilities 
of reclassification provided by PASS-RC for the patients 
who progressed, or who did not, in the PIEM validation 
cohort, which proves the impossibility to identify a good 
discriminative cut-off to be recommended for clinical use. 
The Clinical utility curve (CUC), illustrated in Figure 5, 
highlights the real clinical impact of these findings. 
Selecting different threshold reclassification probabilities 
under those we should not indicate a follow-up Bx, we 
project this value over the two curves in the graphic. 
In one of them, the red one, we can see the percentage of 
saved follow up-Bx and in a parallel fashion, in the blue 
curve, the rate of missed reclassifications. Probably, the 
best threshold corresponds to 13%, which corresponds to a 
23% of potentially saved biopsies at a cost of missing 13% 
reclassifications. Alternatively, in a more conservative 
way, a cut-off of 12%, drives us to a 16% of saved 
biopsies and a 6% of undetected reclassifications (Table 3, 
Figure 5). The decision curve, shown in Figure 6, assessed 
this analysis, there is a narrow range between 18%-38% 
where PASS-RC have utility, but with a poor net benefit 
below 10%.
In addition, we have explored the performance 
of the combination of PASS-RC with the predictors 
BMI, PSA density, PCa length in positive cores and the 
percentage of PCa involvement in those cores. Results are 
shown in Table 4. Only PSA density increase significantly 
the AUC from 0.654 to 0.694 ( p = 0.04).
Table 1: Descriptive characteristics of PASS cohort versus PIEM-AEU- AS validation series
Variable
PIEM-AEU-AS (N = 498) PASS (N = 859)
p-value
N % N %
Age at diagnosis
≤49 5 1,00% 40 4,66% <0,001
50–59 102 20,48% 251 29,22%
60–69 248 49,80% 461 53,67%
70–79 143 28,71% 106 12,34%
≥80 0 0,00% 1 0,12%
Race
White 460 92,37% 783 91,15% <0,001
Black 1 0,20% 43 5,01%
Other-NA 37 7,43% 33 3,84%
PSA at diagnosis, 
ng/mL
0–2.5 11 2,21% 104 12,11% <0,001
2.5–4 83 16,67% 148 17,23%
4–6 193 38,76% 352 40,98%
6–10 176 35,34% 192 22,35%
>10 35 7,03% 53 6,17%
NA 0 0,00% 10 1,16%
T stage at diagnosis
T1a-c 466 93,57% 763 88,82% <0,001
T2a 27 5,42% 92 10,71%
T2b-c 1 0,20% 4 0,47%
Na 4 0,80% 0 0,00%
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DISCUSSION
Active surveillance is becoming more and more 
common in our clinical practice. The unavoidable 
consequences of over-detection in PCa are not synonymous 
of over-treatment because AS contributes to a responsible 
management of patients in low or very low grade and low 
volume PCa [23]. Nevertheless, still many urologists are 
reluctant to offer AS to their patients [24], arguing a lack 
of confidence in conservative management instead of an 
active treatment, and due to uncertainties with their general 
pathologists and radiologists with no specific training in 
mpMRI, or lack of strong evidence that new biomarkers 
could help in this setting [23]. Other non scientific reasons 
could be explained by the need to justify economical and 
technical investments to their health care providers.
Above these arguments, we can mention the 
accumulative evidence of AS efficiency in PCa control of 
series with long follow up [22], showing cancer specific 
survival rates of 99.9% at 15 years with strictest criteria 
[25]. This strong argument minimizes the potential benefit 
in cancer specific survival of active treatment supporters. 
However, the serious implications of AS should be 
carefully explained to the patients. Given the urge for 
evolution, protocols are now trying to become risk-
adapted. Yet, a follow-up Bx is not free of complications 
and it can become a clearly stressful episode and a source 
for discomfort that patients will need to confront. With 
this aim, protocols will need to be simplified due to the 
potential huge amount of AS candidates [26, 27], and the 
predicted costly work overload for Urology Departments.
Is in this context, the PASS initiative for developing 
an Active Surveillance Biopsy Risk Calculator of 
Reclassification/Upgrade should be considered as 
extremely convenient [15]. Previous studies have tried to 
associate PSA kinetics [28], number of previous positive 
Table 2: Biopsy characteristics at diagnosis and at each sequential surveillance biopsy
Characteristics
Biopsy
Diagnosis First Second Third Fourth
PIEM PASS PIEM PASS PIEM PASS PIEM PASS PIEM PASS
Patients, n 1024 979 498 859 100 458 20 211 9 75
Age at biopsy, yr, 
mean (SD)
66.1 (6.9) 62.0 (6.9) 66.5 (7.0) 63.0 (7.0) 66.4 (6.8) 64.4 (6.9) 66.2 (6.1) 65.5 (6.9) 67.1 (4.8) 65.5 (7.2)
Months since last 
biopsy, no, mean 
(SD)
0 (0.0) 0 (0.0) 10.9 (8.9) 12.8 (8.8) 18.4 (8.5) 19.7 (8.3) 18.9 (8.5) 21.1 (7.9) 18.0 (10.0) 20.1 (7.8)
Most recent PSA, 
ng/ml, mean (SD)
6.6 (3.0) 5.5 (3.0) 6.2 (3.5) 5.0 (3.3) 6.3 (3.6) 5.2 (3.6) 6.1 (4.3) 5.4 (3.6) 8.8 (6.1) 5.5 (3.9)
No. of biopsy 
cores, median 
(range)
12 (10–70) 12 (4–60) 16 (10–67) 12 (4–60) 16 
(10–31)
12 (4–46) 18 
(10–24)
12 (4–46) 20 (12–27) 12 (4–34)
Percentage of 
cores positives for 
cancer, n (%)
0 0 (0.0) 0 (0.0) 218 (43.8) 312 (36.3) 49 (49) 190 
(41.5)
10 (50) 88 (41.7) 4 (44.45) 30 (40.0)
>0 and <34 1014 
(99.0)
860 (87.8) 251 (50.4) 465 (54.1) 44 (44) 224 
(48.9)























Gleason score, n 
(%)
≤6 1024 (100) 979 
(100.0)
413 (82.9) 732 (85.2) 83 (83) 384 
(83.8)
19  (95) 166 
(78.7)
7 (77.8) 63 (84.0)
7 0 (0) 0 (0.0) 76 (15.3) 123 (14.3) 13 (13) 70 (15.3) 1 (5) 43 (20.4) 2 (22.2) 10 (13.3)
≥8 0 (0) 0 (0.0) 9 (1.8) 4 (0.5) 4 (4) 4 (0.9) 0 () 2 (1.0) 0 () 2 (2.7)
Outcome
Reclassification 0 (0) 0 (0.0) 94 (18.9) 163 (19.0) 17 (17) 104 
(22.7)
2 (10) 61 (28.9) 2 (22.2) 19 (25.3)
Stable 1024 (100) 897 (91.6) 404 (81.1) 684 (79.6) 83 (83) 347 
(75.8)
18 (90) 149 
(70.6)
7 (77.8) 56 (74.6)
NA — 82 (8.4) 12 (1.4) 7 (1.5) 1 (0.5) 0 (0.0)
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Figure 1: Percentage of reclassification in follow-up biopsies.
Figure 2: Calibration plot of PASS-RC validation in PIEM cohort.
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cores in Bx and PSA density, or Gleason score and PSA 
at baseline [29] to assess the risk of reclassification. The 
PASS Risk Calculator (PASS-RC) calculates the individual 
risk of reclassification in the follow up Bx of patients on 
AS [14, 15]. The internal validation obtained an AUC-
ROC of 0.72, which bears acceptable discrimination 
ability. The authors elegantly claim for external validations 
to test the real capacity of this Risk Calculator before 
recommending its general implementation [15].
In this study we have analyzed the usefulness 
of the PASS-RC in the Spanish Registry on AS, with 
1,024 AS patients included in our Registry at December 
Figure 3: ROC curve of PASS-RC validation in PIEM cohort.
Figure 4: Probability density functions of probability values obtained from PASS-RC in patients with/without 
reclassification in PIEM cohort.
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2015. This registry was opened at September 2014 and 
patients were collected prospective and retrospectively 
from several Spanish series with more evolution on AS; 
but most of them have been included at the beginning of 
their evolution on AS. This is the reason because only 498 
patients have at least one follow-up Bx for the present 
validation. This fact could be considered a limitation, but 
in our opinion the more relevant follow-up Bx on AS is 
the confirmation Bx, the Bx that certificate that the initial 
findings from the initial Bx are real and patients can 
continue on AS with a low risk of underclassification. So 
that we consider are validation focused on confirmation-
Bx specially relevant to validate the clinical useful of 
PASS-RC.  As mentioned, no standardized protocol of 
follow up is defined in our Registry, so each center uses 
its own protocol and defines its own cohort as a real life 
clinical practice on AS, offering PASS-RC the opportunity 
to show its real utility in common clinical practice. 
Statistically, the differences between reference and study 
cohorts (Table 1), rather than representing a drawback, 
offer PASS-RC an adequate opportunity for external 
validation. Thus, our series of 498 patients is older than 
the PASS cohort and shows higher PSA levels than the 
PASS cohort, mainly in the interval 6–10 ng/mL and it is 
more conservative in T stage at diagnosis.
Regarding the results of the first follow up Bx, 
no cancer was found in 43.8% of the cases, compared 
to 36% in the PASS cohort ( p < 0.01). In the following 
follow-up Bx this trend remained the same, without 
any significant difference. Reclassification rates during 
follow up Bx ranged between 10 and 22% in our 
series and between 20 and 30% in the reference series, 
without any statistical differences at any follow-up Bx 
between them (Figure 1). Therefore, we were able to 
unveil a trend to a lower reclassification rate in our 
series and a higher absence, or PCa, at our follow up 
Bx. To date we have been unable to assess if it would 
become statistically significant with a higher sample 
size in the future. Different diagnoses and AS strategies 
could have influenced these different outcomes. At the 
moment, the 2-month mean inferior interval between 
Bx in our cohort is the only objective justification for 
the lower detection of reclassification, particularly in 
cumulative follow-ups.
When we evaluated the correspondence between the 
predicted probabilities of the model in our validation series 
and the real incidence of reclassification, we observed how 
the model underestimates our reality of reclassification, 
mainly in the projection of high probabilities (Figure 2). 
In fact, the probabilities assigned by the model were 
low, ranging between 20 and 50% (Figures 2 and 4), 
are coherent with a series which has a low risk of 
reclassification as the AS series are. The discrimination 
ability was lower in our series (AUC: 0.65 (Figure 3), 
which is common in external validations but compromises 
the clinical utility of the model.
Figure 5: Clinical utility curve: For different threshold probability points selected in X axe, it can be seen in the 
Y axe, on the one hand, in blue line, the percentage of biopsies not performed to patients (Saved biopsy) and, in 
the other hand, in red line, the percentage of patients whose progression have been not been adequately diagnosed 
(Undetected reclassification).
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We also assessed the clinical utility of the model 
through probability density functions [30, 31]. We 
understand it is an excellent tool to choose cut-off points of 
clinical utility in predictive models, nomograms and risk 
calculators. Thus, in Figure 4 we can see the probabilities 
of reclassification provided by PASS-RC for both patients 
who progressed, or who did not, in the PIEM validation 
cohort. We expected higher probabilities of reclassification 
for patients who actually progressed but lower chances for 
the group of patients who did not.
From the distributions of probabilities analyzed, we 
tried to identify a cut-off which separated non-progressive 
patients (ideally, those with low probabilities assigned 
by the model and being under this cut-off) from true-
progressive patients (with assigned probabilities over this 
cut-off point), but we were not able to obtain conclusive 
results. Unfortunately, the assigned probabilities are 
extremely similar in their distributions between both 
subpopulations without the opportunity to identify a 
discriminative cut-off point (Figure 4).
Finally, in an attempt to maximize the evaluation of 
this PASS-RC tool we drew our proposal of clinical utility 
curves as previously [31] (Figure 5). We have shown how 
the range of probabilities for clinical decisions rises from 
Figure 6: Decision curve analysis.
Table 3: Clinical utility cut-offs analysis


















5% to 40%. If we decided not to practice a follow-up Bx 
to patients with a reclassification probability under 13%, 
we would save 23% of preplanned Bx, but would fail to 
detect 13% of the progressive patients in our common 
clinical practice of follow-up Bx, dangerous percentage of 
missing progressive patients especially in protocols where 
the follow-up biopsies are preplanned every three years 
after the confirmatory Bx.
We must acknowledge two main limitations in 
this paper. Firstly, the multicentricity and the lack of a 
standardized protocol of AS management in our entire 
cohort is a fruitful opportunity to externally validate 
PASS-RC in common clinical practice, but could have 
driven to the underdetection or misclassification of 
reclassification. A short follow-up can be mentioned as the 
second limitation of our study and more specifically the 
small sample size included in the last biopsies.
It is now clear that other known series of AS should 
validate the PASS-RC to confirm our findings, given 
that these clinical tools [32–33] are widely used in daily 
practice. As the authors suggest in their publication, we do 
agree that these tools have to be refined with time, using 
longer follow-up, and if possible, using the same common 
inexpensive variables. But they will probably be improved 
with new biomarkers [34–36] or morpho-functional 
parameters from mpMRI, as shown in other models [37]. 
In this sense, we have verified the improvement provided 
by PSA density. We strongly encourage the evaluation of 
this kind of clinical predictive tools – nomograms and 
risk calculators – using our proposed probability density 
functions and clinical utility curves, both in generation 
and validation cohorts. These graphs show the real 
classificatory accuracy of their predictions and help us to 
choose the best cut-off points for clinical use.
CONCLUSIONS
Using the Spanish multicentric registry study on 
AS as a validation cohort, we have obtained a moderate 
discrimination ability of PASS-RC but we found that it 
is not possible to choose a useful cut-off point to made 
adequate decisions in our clinical practice. Other external 
validations, the inclusion of new biomarkers, and especially 
the addition of morpho-functional parameters from mpMRI, 
could be implemented in future investigations to improve 
this model or to generate new ones.
MATERIALS AND METHODS
In the present study, we validate the PASS-RC as 
a predictive tool of the reclassification on follow-up Bx 
for patients on AS with one independent external series 
extracted from the AEU/PIEM/2014/0001 registry. We 
retrospectively and prospectively collected data from 
1,024 patients in a multicentric study which included 36 
Spanish hospitals.
The inclusion criteria were the same as those used 
for the PASS, namely a Gleason score ≤6 and at least 
10 cores on the initial Bx. In addition, the initial PSA 
value was below or equal to 20 ng/ml. No unique follow-
up protocol was determined for the AEU series, so every 
center scheduled their own AS protocol and it does not 
necessarily coincide with the PASS protocol. The outcome 
of our validation was reclassification (or disease upgrade), 
defined by the PASS-RC as either Gleason score upgrade 
from ≤6 to ≥7 and/or as an increase in percentage of 
cancer cores positive for cancer from <34% to ≥34%. A 
comparative descriptive analysis between PIEM and PASS 
cohorts at diagnosis was performed. In order to compare 
both cohorts, the age and PSA variables were categorized 
and statistical significant differences were calculated using 
chi-squared test (Table 1). We also included a comparison 
between both series regarding the data of the follow-up 
Bx (Table 2).
We evaluated the predictive accuracy of the PASS-
RC among our patients performing a standardized 
validation. Firstly, we obtained the probabilities estimated 
in the PIEM cohort using the PASS-RC [14, 15]. 
We drew the calibration curves, which evaluated the 
correspondence between the predicted and the actual 
probabilities of reclassification found in our cohort. Then, 
to study discrimination ability and the clinical utility of 
the model, the empirical distributions of probabilities of 
reclassification in the groups which actually reclassifies 
Table 4: Combined models of PASS-RC analysis
     Reclassification Reclassification AUC test
p-value AUC p-value AUC p-value
PASS-RC < .001 0.654 PASS-RC+
BMI* 0.041 0.577 BMI 0.047 0.653 0.429
PSAD < .001 0.634 PSAD < .001 0.694 0.043
Length+ 0.192 0.551 Length 0.062 0.655 0.933
PCAi++ 0.582 0.512 PCAi 0.792 0.549 0.691
BMI: body mass index. PSAD: PSA density. Length: PCa length in positive cores. PCAi: percentage of PCa involvement in 
biopsy. AUC: area under the ROC curve. BMI, Length and PCAi avalaible for *n = 238, +n = 171; ++n = 176.
Oncotarget108460www.impactjournals.com/oncotarget
or not were graphically shown as the probability density 
functions (PDF) by kernel density estimation [38]. The 
overlap of the probability distributions of both populations 
was important to determine how the model discriminates 
between groups with and without the evaluated event. It 
also shows whether it was possible to choose a threshold 
for clinical application in order to split risk groups for 
reclassification. We proposed this PDF as a very useful 
way to choose the probability thresholds of clinical utility 
in previous validations of prostate cancer estimations 
[30, 31]. Moreover, discrimination was also quantified 
through the Receiver Operating Characteristics (ROC) 
curve [39], the area under the ROC curve (AUC) and its 
95% confidence interval (CI). In order to estimate the 
saved biopsies and the reclassification delayed for different 
probabilities thresholds, we performed a graphical analysis 
through the Clinical utility curve (CUC) that we had 
previously designed to help this kind of clinical decisions 
[31]. Decision curve analysis was used to confirm the 
clinical utility analysis. 
In addition, we explored, as other authors in 
previous studies [40, 41], the variables Body Mass 
index (BMI), PSA density, PCa length in positive cores 
and the percentage of PCa involvement as predictors 
of reclassifications, but here, in order to improve the 
discriminatory ability of PASS-RC. The AUC of PASS-
RC and the combination of the variables with PASS-RC 
were compared using the DeLong Test [42].
Statistical analyses were performed at the two-sided 
0.05 significance level, using R programming language 
v.3.2.1 [43].
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